Paracentesis nursing: the 6–8 g/L albumin rule and SBP diagnosis

Paracentesis is one of the most common bedside procedures performed in patients with liver disease and a core competency for nurses working in med-surg, hepatology, gastroenterology, and critical care. When fluid accumulates in the peritoneal cavity – a condition called ascites – paracentesis provides both a diagnostic window into the underlying cause and a therapeutic option for rapid symptom relief. For nursing students and new graduates, understanding the nurse’s role before, during, and after the procedure is high-yield content for the NCLEX and essential for safe, competent clinical practice.

This guide covers paracentesis from the nursing perspective: indications, preprocedure preparation, the nurse’s procedural role, specimen interpretation (including SAAG calculation and SBP diagnosis), large-volume paracentesis (LVP) with albumin replacement, complication monitoring, and post-procedure patient education. The underlying condition most often driving this procedure is cirrhosis, so pairing this article with the cirrhosis reference will give you the full clinical picture.

What is paracentesis?

Paracentesis is a procedure in which a needle or catheter is inserted through the abdominal wall into the peritoneal cavity to remove ascitic fluid. It is performed at the bedside or in a procedure suite by a physician or advanced practice provider, with the nurse providing preparation, monitoring, specimen management, and post-procedure care.

There are two types based on purpose:

Diagnostic paracentesis removes a small volume (20–60 mL) of ascitic fluid for laboratory analysis. It is used to determine the cause of new-onset ascites or to evaluate for spontaneous bacterial peritonitis (SBP) when infection is suspected.

Therapeutic paracentesis removes a larger volume to relieve the symptoms of tense or refractory ascites – including dyspnea, abdominal pain, and early satiety. When more than 5 liters are removed in one session it is called large-volume paracentesis (LVP), the threshold AASLD 2021 uses for albumin replacement. LVP does not treat the underlying cause; it provides symptomatic relief and requires ongoing management of the primary condition.

Indications and contraindications

AASLD 2021 states that LVP is safe even with coagulopathy: in one study including patients with INR >1.5 and platelets <50 × 10⁹/L, only 1% had minimal skin bleeding. A Mayo Clinic series of 1,100 LVPs (Grabau 2004; mean INR 1.7, mean platelets about 50,000/mm³) had no significant procedure-related complications. Severe hemorrhage does occur, but rarely (0.19% of 4,729 procedures in Pache 2005), and it clustered in patients with advanced liver failure and renal dysfunction rather than in those with the worst INR or platelet values.

Preprocedure nursing care

Thorough preparation reduces procedural risk, improves patient comfort, and ensures accurate specimen collection. Complete these steps before calling the provider to begin.

1. Verify the order and confirm consent Confirm informed consent has been obtained and documented. The provider obtains consent; the nurse verifies it is on the chart before the procedure begins. Ensure the patient understands the procedure, risks (bleeding, infection, bowel perforation), and expected benefits.

2. Assess the patient

• Review recent labs: INR, platelet count, BMP (creatinine, sodium, BUN – baseline for monitoring post-procedure renal function), albumin (needed for SAAG calculation)
• Review current medications – hold diuretics if the patient is already dehydrated
• Assess for allergy to lidocaine (local anesthetic used at insertion site)
• Assess for prior abdominal surgeries (affects site selection)
• Confirm fluid is present on imaging or clinical exam (shifting dullness, fluid wave)

3. Ask the patient to void Have the patient void immediately before the procedure. A full bladder extends into the lower abdomen and significantly increases the risk of bladder perforation during needle insertion. If the patient cannot void spontaneously and the procedure is urgent, bladder catheterization may be required.

4. Position the patient The two standard positions are:

• Supine with the head of the bed elevated 30–45 degrees – fluid pools in the lower abdomen
• Seated upright, leaning slightly forward – fluid pools dependently; preferred for patients with respiratory compromise who cannot lie flat

5. Mark the insertion site (if ultrasound guidance used) The preferred insertion site is the left lower quadrant, about two fingerbreadths (roughly 3 cm) medial and superior to the left anterior superior iliac spine, lateral to the rectus abdominis muscle. This site avoids the inferior epigastric vessels that run within the rectus sheath and is away from the cecum on the right side. In an ultrasound study of 52 patients with cirrhosis (Sakai 2005), the abdominal wall was thinner in the left lower quadrant than at the infraumbilical midline (1.8 vs 2.4 cm) and the fluid was deeper (2.86 vs 2.29 cm). Ultrasound guidance identifies fluid pockets and the bladder; in a database study of 69,859 paracenteses (Mercaldi 2013), it was associated with 68% fewer bleeding complications. The provider marks the site under ultrasound guidance.

6. Set up equipment Gather and prepare the paracentesis tray including:

• Sterile drapes, gloves, and skin antiseptic (chlorhexidine or povidone-iodine)
• Lidocaine 1% with syringe and needle for local anesthesia
• Paracentesis needle or catheter-over-needle (with stopcock and drainage tubing for LVP)
• Vacuum drainage bottles for large-volume drainage
• Specimen tubes for laboratory analysis (see section below)
• Measurement tape (to record abdominal girth)
• Gauze, occlusive dressing

The procedure: nurse’s role

The paracentesis itself is performed by the physician or advanced practice provider. The nurse’s role is active throughout.

Before needle insertion: Position and re-confirm patient, open sterile supplies maintaining asepsis, assist with draping, ensure the patient is calm and understands to remain still.

During needle insertion and initial aspiration: Monitor vital signs continuously (or every 5 minutes for LVP). Ask the patient to report any sudden sharp pain (suggests bowel contact), urge to void (suggests bladder proximity), or dizziness (suggests vasovagal or early hemodynamic compromise). Assist with specimen collection – hand labeled tubes to the provider in the correct order.

During large-volume drainage: Track total volume drained (document in milliliters) and follow any volume cap or rate in the order. Adult guidelines set no standard drainage rate; in the Mayo series, removing a mean of 8.7 L took a mean of 97 minutes (Grabau 2004). Monitor for signs of hypovolemia – hypotension, tachycardia, pallor, dizziness – as the volume climbs. Begin albumin infusion as ordered (see LVP section).

After needle removal: Apply gentle pressure and a sterile occlusive dressing to the puncture site. Note whether fluid is leaking through the dressing – persistent leak is a complication requiring pressure dressing or suture closure.

Ascites fluid analysis: specimen tubes and interpretation

Correct tube selection at the bedside directly affects the accuracy of SBP diagnosis and SAAG calculation. The nurse is typically responsible for labeling tubes, ensuring they are inoculated in the correct order, and transporting them promptly to the laboratory.

SAAG calculation and clinical interpretation

The serum-ascites albumin gradient (SAAG) is a simple calculation that classifies the cause of ascites based on whether portal hypertension is driving fluid accumulation.

Formula:

SAAG = Serum albumin (g/dL) – Ascites albumin (g/dL)

Both values must be drawn on the same day for the calculation to be valid. The serum albumin comes from a standard blood draw; the ascites albumin comes from the paracentesis specimen.

Interpretation:

SAAG ≥1.1 has approximately 97% accuracy in identifying portal hypertension as the underlying mechanism. In a nursing student’s working clinical knowledge, SAAG ≥1.1 means cirrhosis or heart failure until proven otherwise; SAAG <1.1 points toward cancer or infection as primary causes.

Spontaneous bacterial peritonitis (SBP)

SBP is a life-threatening infection of ascitic fluid that occurs without an obvious intra-abdominal source of infection. It develops because ascitic fluid – especially in cirrhotic patients – has low opsonic activity and cannot clear bacterial translocation from the gut effectively.

Diagnosis

SBP is diagnosed when the ascitic fluid PMN count is ≥250 cells/mm³. This threshold is used rather than waiting for culture results because:

• Culture results take 24–48 hours
• Conventional lab culture misses many infections (42–65% detection in older series, per Runyon 1988), and some cases stay culture-negative even with bedside blood culture bottles
• Delaying treatment while awaiting culture results worsens mortality

A PMN count at or above the threshold is treated even when the patient has no symptoms – SBP is often clinically silent in cirrhosis. (AASLD 2021 writes the threshold as above 250 cells/mm³ and the 2009 guidance as 250 or more; in practice they are the same cutoff.)

Clinical signs (may be subtle or absent in cirrhotic patients):

• Fever (may be low-grade or absent in immunocompromised patients)
• Abdominal pain or tenderness
• New or worsening hepatic encephalopathy (often the presenting sign in cirrhosis)
• Nausea, vomiting, diarrhea

Nursing implications for suspected SBP:

1. Obtain paracentesis specimens promptly – PMN count drives treatment before cultures return
2. Inoculate aerobic and anaerobic blood culture bottles at the bedside with at least 10 mL per bottle, before the first antibiotic dose
3. Anticipate and prepare empiric antibiotic orders: a third-generation cephalosporin is first-line where multidrug-resistant organisms are not prevalent, such as cefotaxime 2 g IV – AASLD 2021 gives every 12 hours as its example dose, while the 2009 guidance and many hospital protocols use every 8 hours – for 5–7 days. Ceftriaxone, the other third-generation cephalosporin AASLD names, is a common once-daily alternative; give the dose ordered. Patients with nosocomial SBP, recent hospitalization, or critical illness need broader coverage (for example piperacillin-tazobactam or a carbapenem) because of multidrug-resistant organisms. Treatment begins as soon as ascitic PMN count results are available – do not wait for culture.
4. Monitor for hemodynamic instability – SBP can precipitate hepatorenal syndrome, particularly in patients with elevated bilirubin or creatinine. AASLD 2021 advises holding nonselective beta-blockers (such as propranolol or carvedilol) temporarily if the patient with SBP becomes hypotensive (MAP <65 mm Hg) or develops AKI, so question the dose and notify the provider
5. Expect IV albumin alongside antibiotics: AASLD 2021 recommends 1.5 g/kg on day 1 and 1 g/kg on day 3 for patients with SBP, with the greatest benefit when AKI or jaundice is present (BUN >30 mg/dL, creatinine >1 mg/dL, or bilirubin >5 mg/dL). Older order sets based on the 2009 guidance restrict albumin to creatinine >1 mg/dL, BUN >30 mg/dL, or bilirubin >4 mg/dL. In the Sort trial, albumin cut renal impairment from 33% to 10% and in-hospital mortality from 29% to 10%
6. Repeat paracentesis at 48 hours to confirm treatment response (a PMN fall of less than 25% from baseline signals treatment failure)
7. After recovery, expect long-term secondary prophylaxis: AASLD 2021 recommends daily norfloxacin, or oral ciprofloxacin where norfloxacin is unavailable (it has not been marketed in the US since 2014)

See the peritonitis nursing reference for broader peritonitis assessment and management. For patients who develop renal impairment following SBP, see hepatorenal syndrome nursing.

Large-volume paracentesis and albumin replacement

Large-volume paracentesis (LVP) is defined as removal of more than 5 liters of ascitic fluid in a single session. It is the most effective short-term treatment for tense or refractory ascites, providing faster relief than diuretics alone.

Paracentesis-induced circulatory dysfunction (PICD)

PICD (AASLD 2021 calls it postparacentesis circulatory dysfunction, or PPCD) is the key complication of LVP and the reason albumin replacement is required. Removing a large volume accentuates the arterial vasodilation already present in cirrhosis (Ruiz-del-Arbol 1997), which lowers the effective circulating volume. The renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system respond, causing vasoconstriction and renal hypoperfusion. In research, PICD is defined by a marked rise in plasma renin activity measured about 6 days after the procedure, so it is often silent at the bedside. Its clinical consequences, as listed by AASLD 2021, are renal impairment including hepatorenal syndrome, dilutional hyponatremia, hepatic encephalopathy, and death.

Albumin replacement rule:

For LVP >5 liters: give 6–8 g of IV albumin per liter of ascitic fluid removed (AASLD 2021, based on expert opinion; EASL 2018 uses 8 g per liter)

Example: AASLD 2021 gives about 40 g after 5 liters and about 64 g after 8 liters. Albumin is given as 25% solution (50 mL vials, 12.5 g per vial), typically infused during or immediately after drainage. AASLD notes that PICD risk rises once more than 8 liters are evacuated in a single session, so volumes above that warrant closer hemodynamic monitoring. Smaller taps are not associated with significant hemodynamic change and may not need albumin, but AASLD advises strongly considering albumin even for a smaller volume when the patient has systolic BP <90 mm Hg, serum sodium <130 mmol/L, or AKI.

In a meta-analysis of 17 randomized trials with 1,225 patients (Bernardi 2012), albumin compared with alternatives such as dextran, gelatin, starch, or hypertonic saline reduced PICD (odds ratio 0.39), hyponatremia (OR 0.58), and mortality (OR 0.64).

Key nursing actions for LVP:

• Confirm albumin order is in place before starting drainage
• Have the albumin ready so it can run during or right after drainage, and recalculate the dose if the final volume differs from the plan
• Monitor during and after drainage for hypotension, tachycardia, and oliguria, remembering that PICD itself may produce no signs at first
• Document total drainage volume precisely – the albumin dose is calculated from this
• After the procedure, monitor urine output closely for the first 4–6 hours

LVP treats the symptom but not the disease. Patients on diuretics for ascites management should have their diuretic regimen reviewed after each LVP. Underlying cirrhosis management – salt restriction, diuretics, abstinence from alcohol – must continue.

Complications and nursing monitoring

Post-procedure care and patient education

Post-procedure nursing care

Vital signs: Follow facility policy. A common protocol is blood pressure, heart rate, and respiratory rate every 15 minutes for the first hour, then every 30 minutes for 1–2 hours, before returning to routine monitoring once stable.

Puncture site: Inspect the dressing every 15 minutes for the first hour for leakage or bleeding. Reinforce if saturated; notify the provider if leak is persistent.

Urine output: Monitor hourly urine output for 4–6 hours after LVP. Oliguria (<0.5 mL/kg/hr) is an early sign of PICD or worsening renal function. Report to the provider promptly. For a refresher on monitoring parameters, see the vital signs nursing reference.

Abdominal girth: Measure and document abdominal girth after the procedure as a baseline for future comparison.

Laboratory monitoring: Expect post-procedure orders for a BMP (creatinine, sodium, potassium) and repeat liver tests depending on clinical context, since rising creatinine and falling sodium are the measurable signs of PICD. Review results and notify provider of concerning trends.

Albumin infusion: If not already completed, ensure the albumin infusion is running and administered in full. Document total albumin administered and patient response.

Positioning: Keep the patient in a position of comfort. Patients often feel immediate relief from dyspnea after LVP – reassure them this is expected.

Patient education

Patients with chronic ascites from cirrhosis or other conditions will likely require repeated paracentesis. Teaching them about self-monitoring and lifestyle modifications reduces the frequency of procedures and the risk of SBP.

Sodium restriction: Limit dietary sodium to less than 2 grams (2,000 mg) per day, the AASLD 2021 target. Sodium drives water retention and directly contributes to ascites re-accumulation. AASLD suggests considering a formal dietitian consultation, partly to guard against malnutrition on a low-salt diet.

Daily weights: Weigh yourself every morning after voiding, before eating, in the same clothing, and call the provider when the weight moves outside the range they set. Steady gain usually means fluid is returning. Losing too fast is also a risk: AASLD 2021 notes that in patients without leg swelling, diuretic weight loss beyond about 0.5 kg (1 lb) per day can shrink the circulating volume and cause kidney injury and low sodium.

Recognizing recurrence: Teach patients the symptoms of worsening ascites: increasing abdominal fullness or tightness, shortness of breath when lying flat (orthopnea), or visible abdominal distension. These warrant prompt medical evaluation.

Signs of SBP to report: Fever (temperature above 38°C / 100.4°F), chills, worsening abdominal pain, new confusion, or nausea/vomiting. Any of these in a patient with known ascites should trigger immediate medical evaluation – SBP can deteriorate rapidly. For infection prevention principles, see the infection control reference.

Alcohol abstinence: For patients with alcohol-related cirrhosis, abstinence is the most effective step they can take to slow disease progression and reduce the frequency of ascites episodes.

Medication adherence: Diuretics (spironolactone and furosemide) only work when taken consistently. Do not skip doses or self-adjust doses without provider guidance. Report dizziness, muscle cramps, or decreased urination – these may indicate a dose adjustment is needed.

Follow-up appointments: Patients with cirrhosis and ascites require regular monitoring of renal function, electrolytes, and hepatic function. Emphasize the importance of keeping these appointments even when feeling well.

NCLEX tips: paracentesis nursing high-yield review

• Bladder voiding before paracentesis is a priority nursing action – it prevents bladder perforation during needle insertion.
• The preferred insertion site for paracentesis is the left lower quadrant, lateral to the rectus abdominis sheath, to avoid the epigastric vessels.
• A PMN count of ≥250 cells/mm³ in ascitic fluid is diagnostic of SBP – treatment begins before culture results return, with a third-generation cephalosporin such as cefotaxime 2 g IV (every 12 hours in the AASLD 2021 example; every 8 hours in older protocols) plus IV albumin.
• Blood culture bottles inoculated at the bedside (at least 10 mL each, before antibiotics) detect far more SBP than plain specimen tubes: 93% vs 43% in Runyon 1988.
• SAAG = serum albumin minus ascites albumin. SAAG ≥1.1 = portal hypertension (cirrhosis, heart failure, Budd-Chiari). SAAG <1.1 = non-portal cause (malignancy, TB, nephrotic syndrome). With a high SAAG, ascitic protein >2.5 g/dL points to heart failure.
• For LVP >5 liters: albumin 6–8 g per liter removed IV (AASLD 2021) to prevent PICD and hepatorenal syndrome.
• PICD is often silent at first; watch for rising creatinine, falling sodium, hypotension, and oliguria in the days after LVP – albumin replacement is the prevention strategy.
• New-onset confusion after paracentesis in a cirrhotic patient is hepatic encephalopathy until proven otherwise – assess for precipitating factors (infection, bleeding, electrolyte shifts, sedatives); the ACG 2026 guideline advises against using an ammonia level alone to diagnose it or guide treatment.
• Sudden severe abdominal pain during needle insertion suggests bowel perforation – stop the procedure immediately and notify the provider.
• Dilutional hyponatremia can worsen after LVP – monitor sodium post-procedure; AASLD 2021 uses fluid restriction to about 1,000 mL/day for sodium 120–125 mEq/L.
• Patients should void before paracentesis, not after – this is a pre-procedure preparation step, not post-procedure care.
• A raised INR or low platelet count is not a contraindication in cirrhosis, and AASLD 2021 does not recommend routine FFP or platelet transfusion before diagnostic or large-volume paracentesis.
• For cytology (suspected malignancy), send a generous fresh specimen; it is positive in about 97% of peritoneal carcinomatosis but usually negative with liver metastases or hepatocellular carcinoma alone.
• After LVP, follow facility policy for vital signs; every 15 minutes for the first hour is a common protocol.
• Persistent fluid leak at the puncture site may require suture closure – apply a pressure dressing and notify the provider.

Related skills and references

For the underlying conditions most commonly driving paracentesis, review:

• Cirrhosis nursing – pathophysiology, Child-Pugh staging, and complication management
• Hepatorenal syndrome nursing – the renal complication most feared after LVP and SBP
• Hepatic encephalopathy nursing – grading, triggers, and nursing interventions for the post-paracentesis neurological complication
• Peritonitis nursing – recognizing and responding to peritoneal infection
• Infection control and isolation precautions – aseptic technique principles relevant to bedside procedures
• ABG interpretation – for interpreting respiratory compromise from tense ascites
• Nursing lab values cheat sheet – quick reference for albumin, INR, platelets, and renal function values relevant to paracentesis preparation

References

1. European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460. doi:10.1016/j.jhep.2018.03.024

2. Runyon BA; AASLD Practice Guideline Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49(6):2087–2107. doi:10.1002/hep.22853 (superseded by the 2021 AASLD guidance, reference 13)

3. Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012;55(4):1172–1181. doi:10.1002/hep.24786

4. Arroyo V, Ginès P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996;23(1):164–176. doi:10.1002/hep.510230122

5. Ginès P, Uriz J, Calahorra B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology. 2002;123(6):1839–1847. doi:10.1053/gast.2002.37073

6. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403–409. doi:10.1056/NEJM199908053410603

7. Felisart J, Rimola A, Arroyo V, et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology. 1985;5(3):457–462. doi:10.1002/hep.1840050319

8. Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology. 1988;95(5):1351–1355. doi:10.1016/0016-5085(88)90372-1

9. Bernardi M, Caraceni P, Navickis RJ. Does the evidence support a survival benefit of albumin infusion in patients with cirrhosis undergoing large-volume paracentesis? Expert Rev Gastroenterol Hepatol. 2017;11(3):191–192. doi:10.1080/17474124.2017.1275961

10. Kuiper JJ, van Buuren HR, de Man RA. Ascites in cirrhosis: a review of management and complications. Neth J Med. 2007;65(8):283–288.

11. Moore CM, Van Thiel DH. Cirrhotic ascites review: pathophysiology, diagnosis, and management. World J Hepatol. 2013;5(5):251–263. doi:10.4254/wjh.v5.i5.251

12. Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62(4):968–974. doi:10.1016/j.jhep.2014.12.029

13. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014–1048. doi:10.1002/hep.31884

14. Altman C, Grange JD, Amiot X, et al. Survival after a first episode of spontaneous bacterial peritonitis – prognosis of potential candidates for orthotopic liver transplantation. J Gastroenterol Hepatol. 1995;10(1):47–50. doi:10.1111/j.1440-1746.1995.tb01046.x

15. Thevenot T, Bureau C, Oberti F, et al. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis – a randomized trial. J Hepatol. 2015;62(4):822–830. doi:10.1016/j.jhep.2014.11.017

16. Ruiz-del-Arbol L, Monescillo A, Jiménez W, Garcia-Plaza A, Arroyo V, Rodés J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology. 1997;113(2):579–586. doi:10.1053/gast.1997.v113.pm9247479

17. Grabau CM, Crago SF, Hoff LK, et al. Performance standards for therapeutic abdominal paracentesis. Hepatology. 2004;40(2):484–488. doi:10.1002/hep.20317

18. Pache I, Bilodeau M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment Pharmacol Ther. 2005;21(5):525–529. doi:10.1111/j.1365-2036.2005.02387.x

19. De Gottardi A, Thévenot T, Spahr L, et al. Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Gastroenterol Hepatol. 2009;7(8):906–909. doi:10.1016/j.cgh.2009.05.004

20. Sakai H, Sheer TA, Mendler MH, Runyon BA. Choosing the location for non-image guided abdominal paracentesis. Liver Int. 2005;25(5):984–986. doi:10.1111/j.1478-3231.2005.01149.x

21. Mercaldi CJ, Lanes SF. Ultrasound guidance decreases complications and improves the cost of care among patients undergoing thoracentesis and paracentesis. Chest. 2013;143(2):532–538. doi:10.1378/chest.12-0447

22. Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology. 1988;8(5):1104–1109. doi:10.1002/hep.1840080521

23. Bajaj JS, et al. ACG clinical guideline: hepatic encephalopathy. Am J Gastroenterol. 2026;121(3):588–618. doi:10.14309/ajg.0000000000003899